Nurix Therapeutics Presents New Data Demonstrating Durable, Deepening Responses in Phase 1 Trial of Bexobrutideg (NX-5948) in Patients with Relapsed or Refractory Chronic Lymphocytic Leuke...
Nurix Therapeutics, Inc. - Common stock (NRIX)
Company Research
Source: GlobeNewswire
Objective response rate (ORR) of 83% including two complete responses in CLL patients in Phase 1a study with median progression free survival (PFS) of 22.1 months across all doses tested Emerging data from randomized Phase 1b cohorts points to higher ORR and longer progression free survival at the 600 mg recommended Phase 2 dose (RP2D) compared to the 200 mg dose Bexobrutideg was well tolerated with a consistent safety profile between the 600 mg RP2D and the overall study population Phase 2 clinical trial of bexobrutideg (DAYBreak-CLL-201) currently enrolling globally Company will host a webcast to discuss the data on Monday, December 8, 2025, at 8:15 p.m. ET BRISBANE, Calif., Dec. 06, 2025 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted protein degradation medicines in oncology and autoimmune disease, today announced new clinical data from the Compan
Show less
Read more
Impact Snapshot
Event Time:
NRIX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
NRIX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
NRIX alerts
High impacting Nurix Therapeutics, Inc. - Common stock news events
Weekly update
A roundup of the hottest topics
NRIX
News
- Nurix Therapeutics (NASDAQ:NRIX) had its price target raised by analysts at Mizuho from $24.00 to $30.00. They now have an "outperform" rating on the stock.MarketBeat
- Nurix Therapeutics (NASDAQ:NRIX) had its "buy" rating reaffirmed by analysts at HC Wainwright.MarketBeat
- Nurix Therapeutics (NASDAQ:NRIX) had its "buy" rating reaffirmed by analysts at BTIG Research.MarketBeat
- Nurix Therapeutics (NASDAQ:NRIX) had its "buy" rating reaffirmed by analysts at Needham & Company LLC. They now have a $26.00 price target on the stock.MarketBeat
- Nurix Therapeutics Presents New Data from the Phase 1 Trial of Bexobrutideg (NX-5948) in Waldenström Macroglobulinemia at the 67th American Society of Hematology (ASH) Annual Meeting and ExpositionGlobeNewswire
NRIX
Earnings
- 10/9/25 - Miss
NRIX
Sec Filings
- 12/9/25 - Form 8-K
- 11/24/25 - Form 4
- 11/24/25 - Form 144
- NRIX's page on the SEC website